Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Saved in:
| Title: | Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). |
|---|---|
| Authors: | Garg SK; Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Wernicke-Panten K; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany., Wardecki M; Sanofi, Warszawa, Poland., Kramer D; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany., Delalande F; Ividata, Paris, France., Franek E; Mossakowski Clinical Research Centre, Polish Academy of Sciences, and CSK MSWiA, Warszawa, Poland., Sadeharju K; Terveystalo Seinäjoki, Seinäjoki, Finland., Monchamp T; Endocrinology Services Northwest, Bend, Oregon., Mukherjee B; Sanofi, Paris, France., Shah VN; Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado. |
| Source: | Diabetes technology & therapeutics [Diabetes Technol Ther] 2020 Feb; Vol. 22 (2), pp. 85-95. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial |
| Journal Info: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100889084 Publication Model: Print Cited Medium: Internet ISSN: 1557-8593 (Electronic) Linking ISSN: 15209156 NLM ISO Abbreviation: Diabetes Technol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1557-8593 |
|---|---|
| DOI: | 10.1089/dia.2019.0382 |
